|
23 Sep 2021 |
Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
|
|
23 Sep 2021 |
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
|
|
22 Sep 2021 |
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
|
|
20 Sep 2021 |
Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer
|
|
20 Sep 2021 |
Pfizer and BioNTech Announce Positive Topline Results from Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
|
|
18 Sep 2021 |
Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial
|
|
18 Sep 2021 |
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
|
|
15 Sep 2021 |
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
|
|
15 Sep 2021 |
Oragenics Initiates COVID-19 Challenge Study Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
|
|
15 Sep 2021 |
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19
|
|
15 Sep 2021 |
HOOKIPA announces clinical collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to evaluate HB-200 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced head and neck cancers
|
|
15 Sep 2021 |
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
|
|
15 Sep 2021 |
Providence Therapeutics Reports PTX-COVID19-B, its mRNA Vaccine for COVID-19, Neutralizes SARS-CoV-2 and Variants of Concern, Including Delta
|
|
09 Sep 2021 |
New Research on SINOVAC’s COVID-19 Vaccine Shows Third Dose More Effective Against COVID-19, including the Delta Variant
|
|
09 Sep 2021 |
Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for COVID-19 and Seasonal Influenza
|
|
04 Sep 2021 |
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
|
|
02 Sep 2021 |
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
|
|
02 Sep 2021 |
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
|
|
02 Sep 2021 |
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate
|
|
01 Sep 2021 |
Entos Pharmaceuticals' COVID-19 DNA Vaccine Candidate Approved for Phase 2 Clinical Trial in South Africa
|
|
01 Sep 2021 |
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
|
|
31 Aug 2021 |
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India
|
|
31 Aug 2021 |
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
|
|
31 Aug 2021 |
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
|
|
26 Aug 2021 |
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
|
